Skip to content
Biodatica
Start free

Investigator

Roger S Lo

UNIVERSITY OF CALIFORNIA LOS ANGELES · funded by NCI

Companies
1

Resolved onto their grants.

Grants
5

Federal awards on file.

Non-dilutive funding
$3.1M

Summed across those awards.

First award
Sep 4, 2013

Latest Mar 1, 2024.

Companies from this work

Pre-ticker companies the crosswalk resolved onto a grant filed under this investigator. Momentum shows for the therapeutic areas your seat covers; open a dossier for the full crosswalk.

Grant record

Federal awards filed under this investigator name, newest first. Each links to the public record where the awarding agency publishes one.

  1. R01

    Melanoma Resistance Evolution Atlas (MREA) for identifying combinatorial targets to prevent and reverse MAPKi resistance

    $647k

    Mar 1, 2024NCIUNIVERSITY OF CALIFORNIA LOS ANGELESNIH RePORTER · 11045705 (opens the source filing in a new tab)

  2. R01

    Melanoma Resistance Evolution Atlas (MREA) for identifying combinatorial targets to prevent and reverse MAPKi resistance

    $647k

    Mar 1, 2024NCIUNIVERSITY OF CALIFORNIA LOS ANGELESNIH RePORTER · 11295389 (opens the source filing in a new tab)

  3. U54

    Core 1: Mouse Model and Tissue Biobank Core

    $260k

    Sep 22, 2022NCIINSTITUTE FOR SYSTEMS BIOLOGYNIH RePORTER · 11191436 (opens the source filing in a new tab)

  4. R01

    Preventing MAPK inhibitor resistance in melanoma by targeting genomic instability and immune resistance

    $394k

    Sep 4, 2013NCIUNIVERSITY OF CALIFORNIA LOS ANGELESNIH RePORTER · 11182693 (opens the source filing in a new tab)

  5. R01

    Preventing MAPK inhibitor resistance in melanoma by targeting genomic instability and immune resistance

    $1.2M

    Sep 4, 2013NCIUNIVERSITY OF CALIFORNIA LOS ANGELESNIH RePORTER · 11360720 (opens the source filing in a new tab)

This page aggregates public U.S. federal grant records filed under one investigator name and the companies Biodatica has resolved onto them. Names are shown as the awarding agency filed them; grant awards are non-dilutive federal funding, not equity or valuation. Distinct people who file under the same name would appear together here. It is informational only and not investment advice. Methodology · Data sources